Surgical Interventions during STI 571 Treatment of Metastatic GIST: Experience in Six Patients

References

• TuvESON D. A., Willis N. A., Jacks T. et al. STI 571 inactivation of gastrointestinal stromal tumour c-KIT oncoprotein: Biological and clinical implications. Oncogene, 2001, 20: 5054–8.
   Google Scholar
• Fletcher C. D. M., Berman J. J., Corless C. et al. Diagnosis of gastrointestinal stromal tumours: A consensus approach. Hum Pah, 2002, 33: 459–65.
   Google Scholar
• Miettinen M., El-Rifai W., Sobin L. H., Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumours: A review. Hum Path, 2002, 33: 478–483.
   Google Scholar
• Hirota S., Isozaki K., Moriyama Y. et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumours. Science, 1998, 279: 577–80.
   Google Scholar
• Rubin B. P., Singer S., Tsao C. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumours. Canc Res, 2001, 61: 8118–21.
   Google Scholar
• Debiec-Rychter M., Lasota J., Sarlomo-Rikala M., Kordek R., Miettinen M. Chromosal aberrations in malignant gastrointestinal stromal tumours: correlation with c-KIT gene mutation. Canc Gen Cyt, 2001, 128: 24–30.
   Google Scholar
• Allander S. V., Nupponen N. N., Ringnér M. et al. Gastrointestinal stromal tumours with KIT mutations exhibit a remarkably homogeneous gene expression profile. Canc Res, 2001, 61: 8624–8.
   Google Scholar
• Heinrich M. C., Rubin B. P., Longley B. J., Fletcher J. A. Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations. Hum Path, 2002, 33: 484–95.
   Google Scholar
• Druker B. J., Tamura S., Buchdunger E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med, 1996, 2: 561–6.
   Google Scholar
• Druker B. J., Talpaz M., Resta D. J. et al. Efficacy and safety of a specific inhibitor of the BcR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med, 2001, 344: 1031–7.
   Google Scholar
• Druker B. J., Sawyers C. L., Kantarjian H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. NEng J Med, 2001, 344: 1038–42.
   Google Scholar
• Buchdunger E., Zimmerman J., Mett H. et al. Inhibition of the ABL protein-tyrosine kinase in vitro and in vivo by a 2-pheny-laminopyrimidine derivative. Cancer Res, 1996, 56: 100–4.
   Google Scholar
• Heinrich M. C., Griffith D. J., Druker B. J., Wait C. L., Ott K. A., Zigler A. J. Inhibition of a c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. 2000. Blood, 2000, 96: 925–32.
   Google Scholar
• Buchdunger E., Cioffi C. L., Law N. et al. ABL protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 2000, 295: 139–45.
   Google Scholar
• Joenssuu H., Roberts P. J., Sarlomo-Rikala M. et al. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumour. N Eng J Med, 2001, 344: 105–26.
   Google Scholar
• Dematteo R. P., Heinrich M. C., El-Rifai W. M., Demetri G. Clinical management of gastrointestinal stromal tumours: Before and after STI-571. Hum Path, 2002, 33: 466–77.
   Google Scholar
• van Oosterom A. T., Judson I., Verweij J. et al. Safety and efficacy of imanitib (STI 571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 2001, 358: 1421–3.
   Google Scholar
• Eggermont A. M. M., Schraffordt-Koops H., Klausner J. M. et al. Isolated limb perfusion with tumour necrosis factor and Melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg, 1996, 224: 756–65.
   Google Scholar
• Bartlett D. L., Ma G., Alexander H. R., Libutti S. K., Fraker D. L. Isolated limb perfusion with tumour necrosis factor and Melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer, 1997, 80: 2084–90.
   Google Scholar